Related references
Note: Only part of the references are listed.Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors
Fanny Lalloyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells
Fariborz Rashid-Kolvear et al.
BMC CANCER (2010)
The Role of T cell PPARγ in mice with experimental inflammatory bowel disease
Amir J. Guri et al.
BMC GASTROENTEROLOGY (2010)
Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone
Jung Ok Ban et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2010)
Combination peroxisome proliferator-activated receptor γ and α agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content
R. Balasubramanian et al.
DIABETIC MEDICINE (2010)
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
P. D. Home et al.
DIABETOLOGIA (2010)
Inhibitory Role of Peroxisome Proliferator-Activated Receptor Gamma in Hepatocarcinogenesis in Mice and In Vitro
Jun Yu et al.
HEPATOLOGY (2010)
Cytotoxic Flavonoids as Agonists of Peroxisome Proliferator-Activated Receptor γ on Human Cervical and Prostate Cancer Cells
Jee-Young Lee et al.
JOURNAL OF NATURAL PRODUCTS (2010)
SIRT1 is regulated by a PPARγ-SIRT1 negative feedback loop associated with senescence
Limin Han et al.
NUCLEIC ACIDS RESEARCH (2010)
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon
Laurent Peyrin-Biroulet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Anticancer Role of PPAR gamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes
P. J. Simpson-Haidaris et al.
PPAR RESEARCH (2010)
Role of PPARs in Radiation-Induced Brain Injury
Sriram Ramanan et al.
PPAR RESEARCH (2010)
PPARs and Anticancer Therapies
Michael E. C. Robbins et al.
PPAR RESEARCH (2010)
Therapeutic Implications of PPAR gamma in Human Osteosarcoma
Eric R. Wagner et al.
PPAR RESEARCH (2010)
Combined Low Doses of PPARγ and RXR Ligands Trigger an Intrinsic Apoptotic Pathway in Human Breast Cancer Cells
Daniela Bonofiglio et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Activation of Peroxisome Proliferator-Activated Receptor β/δ Induces Lung Cancer Growth via Peroxisome Proliferator-Activated Receptor Coactivatior γ-1α
ShouWei Han et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2009)
Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells
Shima Kumei et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Peroxisome proliferator-activated receptor γ in bladder cancer A promising therapeutic target
Jose J. Mansure et al.
CANCER BIOLOGY & THERAPY (2009)
Activating Peroxisome Proliferator-Activated Receptor γ Mutant Promotes Tumor Growth In vivo by Enhancing Angiogenesis
Lifeng Tian et al.
CANCER RESEARCH (2009)
Differential Presentation of Protein Interaction Surfaces on the Androgen Receptor Defines the Pharmacological Actions of Bound Ligands
John David Norris et al.
CHEMISTRY & BIOLOGY (2009)
Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: Association with differentiation, proliferation and clinical outcome
E. Mylona et al.
EJSO (2009)
Colorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor γ (PPARG, PPARgamma) Is Associated With Good Prognosis
Shuji Ogino et al.
GASTROENTEROLOGY (2009)
PPARγ and RXRγ ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models
Alessio Papi et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
The Effect of the PPAR-gamma Agonist Rosiglitazone on Neuroblastoma SK-N-SH Cells in a Metastatic Xenograft Mouse Model
Nina Krieger-Hinck et al.
ONCOLOGY RESEARCH (2009)
Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells
Chan Woo Cheon et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor γ involves angiogenesis inhibition
Yu-Wei Dong et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-gamma and Plasminogen Activator Inhibitor-1
Jennifer C. Carter et al.
PPAR RESEARCH (2009)
PPARβ/δ agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression:: the involvement of PI3K and NF-κB signals
ShouWei Han et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2008)
Peroxisome Proliferator-Activated Receptor β/δ Expression and Activation in Lung Cancer
Tetyana V. Pedchenko et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease
K. N. Prasad et al.
ANNALS OF ONCOLOGY (2008)
PPARγ agonists inhibit growth and expansion of CD133+brain tumour stem cells
W. Chearwae et al.
BRITISH JOURNAL OF CANCER (2008)
Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator-Activated Receptor γ
Raphael Nemenoff et al.
CANCER PREVENTION RESEARCH (2008)
Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor γ agonist in an in vivo mouse model of spontaneous breast cancer
Aladdin Mustafa et al.
CLINICAL CANCER RESEARCH (2008)
Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptorγ ligands in vitro and in vivo
Ming-Chuan Hsu et al.
CLINICAL CANCER RESEARCH (2008)
Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin
Geoffrey D. Girnun et al.
CLINICAL CANCER RESEARCH (2008)
Rosiglitazone and risk of cancer - A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES CARE (2008)
Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
Ronald A. Lubet et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Peroxisome Proliferator-activated Receptor γ Down-regulates Follistatin in Intestinal Epithelial Cells through SP1
Brian M. Necela et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Peroxisome proliferator-activated receptor γ and lung cancer biology
Jesse Roman
JOURNAL OF INVESTIGATIVE MEDICINE (2008)
PPARα:: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators
Frank J. Gonzalez et al.
TOXICOLOGY (2008)
Troglitazone, a peroxisome proliferator-activated receptor γ ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells
Yan-Ming Zhou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
Terry Lichtor et al.
PPAR RESEARCH (2008)
Role of Peroxisome Proliferator-Activated Receptor Gamma and Its Ligands in the Treatment of Hematological Malignancies
TatianaM. Garcia-Bates et al.
PPAR RESEARCH (2008)
PPARs and RXRs in Male and Female Fertility and Reproduction
P. Froment
PPAR RESEARCH (2008)
The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer
Guido Eibl
PPAR RESEARCH (2008)
The Role of PPAR gamma in the Cyclooxygenase Pathway in Lung Cancer
Saswati Hazra et al.
PPAR RESEARCH (2008)
The Role of PPAR gamma in Hepatocellular Carcinoma
Ivan Borbath et al.
PPAR RESEARCH (2008)
The Role of PPAR gamma Receptors and Leukotriene B-4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer
Thomas E. Adrian et al.
PPAR RESEARCH (2008)
Rat Urinary Bladder Carcinogenesis by Dual-Acting PPAR alpha plus gamma Agonists
Martin B. Oleksiewicz et al.
PPAR RESEARCH (2008)
PPARs: A Double-Edged Sword in Cancer Therapy?
Dipak Panigrahy et al.
PPAR RESEARCH (2008)
Synergistic Effects of PPAR gamma Ligands and Retinoids in Cancer Treatment
Masahito Shimizu et al.
PPAR RESEARCH (2008)
Chemotherapeutic drugs induce PPAR-Y expression and show sequence-specific synergy with PPAR-Y ligands in inhibition of non-small cell lung cancer
Rajuc C. Reddy et al.
NEOPLASIA (2008)
Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in japanese
Tomomitsu Tahara et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
The PPAR alpha-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPAR alpha
Qian Yang et al.
TOXICOLOGICAL SCIENCES (2008)
Time course investigation of PPARα- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression
Courtney G. Woods et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2007)
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines
Holly E. Hollingshead et al.
CARCINOGENESIS (2007)
Differential expression, distribution, and function of PPAR-γ in the proximal and distal colon
Weidong Su et al.
PHYSIOLOGICAL GENOMICS (2007)
Safety issues and prospects for future generations of PPAR modulators
Anne Rubenstrunk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
PPARs in the brain
Michael T. Heneka et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver
I. Borbath et al.
EUROPEAN JOURNAL OF CANCER (2007)
Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells
Liang-qi Cao et al.
ACTA PHARMACOLOGICA SINICA (2007)
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Rangaswamy Govindarajan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-γ agonists induced apoptosis in human monocyte leukemia cells in vitro
Jia-Jun Liu et al.
ANNALS OF HEMATOLOGY (2007)
Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects
Fang Zhang et al.
PPAR RESEARCH (2007)
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-Gamma Agonists in recurrent high-grade gliomas - A phase II study
P. Hau et al.
ONCOLOGY (2007)
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
Electron Kebebew et al.
SURGERY (2006)
Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times
Glen Kristiansen et al.
CLINICAL CANCER RESEARCH (2006)
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment
Christian Grommes et al.
MOLECULAR PHARMACOLOGY (2006)
Halofenate is a selective peroxisome proliferator-activated receptor γ modulator with antidiabetic activity
Tamara Allen et al.
DIABETES (2006)
RS5444, a novel PPAR-γ agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells
Lu Chen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2006)
Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis
K Morimura et al.
CARCINOGENESIS (2006)
From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
JN Feige et al.
PROGRESS IN LIPID RESEARCH (2006)
Inhibition of bladder tumor growth by 1,1-bis(3 '-indolyl)-1-(p-substitutedphenyl)methanes: A new class of peroxisome proliferator-activated receptor gamma agonists
W Kassouf et al.
CANCER RESEARCH (2006)
Peroxisome proliferator-activated receptor δ as a molecular target to regulate lung cancer cell growth
K Fukumoto et al.
FEBS LETTERS (2005)
Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice
J Lu et al.
CANCER RESEARCH (2005)
A novel ring-substituted diindolylmethane, 1,1-bis[3′-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia
R Contractor et al.
CANCER RESEARCH (2005)
Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells
KL Schaefer et al.
CANCER RESEARCH (2005)
Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-γ ligands induces apoptosis on human myeloid leukemia cells in vitro
JJ Liu et al.
ANNALS OF ONCOLOGY (2005)
PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer
VG Keshamouni et al.
NEOPLASIA (2005)
Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)
Y Bren-Mattison et al.
ONCOGENE (2005)
Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas
MW Matthiessen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2005)
Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis
FS Harman et al.
NATURE MEDICINE (2004)
PPARγ signaling exacerbates mammary gland tumor development
E Saez et al.
GENES & DEVELOPMENT (2004)
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth
RA Gupta et al.
NATURE MEDICINE (2004)
Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells
W Motomura et al.
JOURNAL OF GASTROENTEROLOGY (2004)
A phase II trial with rosiglitazone in liposarcoma patients
G Debrock et al.
BRITISH JOURNAL OF CANCER (2003)
Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferatoractivated receptor γ/retinoid X receptor α pathway
M Tsujie et al.
EXPERIMENTAL CELL RESEARCH (2003)
Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer
L Jackson et al.
GUT (2003)
PPARδ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells
B Glinghammar et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer:: a phase II study
HJ Burstein et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E-2 and 15-deoxy-Delta(12.14)-prostaglandin J(2) in human breast cancer and metastasis
AF Badawi et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells
K Hellemans et al.
GASTROENTEROLOGY (2003)
A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
MH Kulke et al.
CANCER JOURNAL (2002)
Expression of peroxisome proliferator-activate D receptors in human testicular cancer and growth inhibition by its agonists
T Hase et al.
UROLOGY (2002)
Ligand activation of peroxisome proliferator-activated receptor γ induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockade of the Tcf-4 activity
N Yamakawa-Karakida et al.
CELL DEATH AND DIFFERENTIATION (2002)
A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells
M Toyoda et al.
GUT (2002)
Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer
H Sasaki et al.
LUNG CANCER (2002)
Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells
T Satoh et al.
ONCOGENE (2002)
Peroxisome proliferator-activated receptor γ reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1
M Toyota et al.
LIFE SCIENCES (2002)
Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer
Y Barak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFα signaling
SP Anderson et al.
CARCINOGENESIS (2001)
Peroxisome proliferator-activated receptors in inflammation control
P Delerive et al.
JOURNAL OF ENDOCRINOLOGY (2001)
Tumor necrosis factor a is not required for WY14,643-induced cell proliferation
JW Lawrence et al.
CARCINOGENESIS (2001)
Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells
K Uchimura et al.
HEPATOLOGY (2001)
Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
H Sato et al.
BRITISH JOURNAL OF CANCER (2000)
Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
G Chinetti et al.
INFLAMMATION RESEARCH (2000)
Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis
Y Tsubouchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Peroxisome proliferator-activated receptor α is restricted to hepatic parenchymal cells, not Kupffer cells:: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis
JM Peters et al.
CARCINOGENESIS (2000)
Share Paper
